Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.33 |
| ▸ | MME | P08473 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10824186 | 0.98 | CYP2C19 (0.52) | CYP2C19MEN1KMT2AALDH1A1POLB | |
| SCHEMBL11634222 | 0.98 | CYP2C19 (0.50) | CYP2C19MEN1KMT2AALDH1A1POLB | |
| SCHEMBL16151058 | 0.93 | CYP2C19 (0.45) | CYP2C19MEN1KMT2AALDH1A1POLB | |
| SCHEMBL11664080 | 0.89 | CYP2C19 (0.38) | CYP2C19MEN1KMT2AALDH1A1POLB | |
| SCHEMBL517571 | 0.89 | — | — | |
| SCHEMBL11498095 | 0.84 | CYP2C19 (0.40) | CYP2C19MEN1KMT2AALDH1A1POLB | |
| SCHEMBL10824184 | 0.81 | CYP2C19 (0.38) | CYP2C19MEN1KMT2AALDH1A1POLB | |
| SCHEMBL11264036 | 0.81 | CYP2C19 (0.38) | CYP2C19MEN1KMT2AALDH1A1POLB | |
| SCHEMBL29308999 | 0.81 | CYP2C19 (0.38) | CYP2C19MEN1KMT2AALDH1A1POLB | |
| SCHEMBL8437124 | 0.80 | CYP2C19 (0.56) | CYP2C19ALDH1A1TBXAS1MMEUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0222157-B1 | RESIN COMPOSITION | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1992-12-30 | — | — | EP | claimed |
| US-4886862-A | MOISTURE-CURABLE SILYL-GROUP CONTAINING COPOLYMER OF A FLUOROALKYL PERVINYL ETHER AND A VINYL CARBOXYLATE, CATALYST AND SOLVENT; PAINTS; COATINGS, WEATHERPROOFING; HARDNESS | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1989-12-12 | — | — | US | claimed |
| EP-0222157-A2 | Resin composition | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1987-05-20 | — | — | EP | claimed |
| US-4544767-A | HYDROGENATION CATALYST | PHILLIPS PETROLEUM COMPANY (US) | 1985-10-01 | — | — | US | claimed |
| JP-6128196-A | — | — | None | — | — | JP | disclosed |
| JP-4100891-A | — | — | None | — | — | JP | disclosed |
| JP-57192336-A | — | — | None | — | — | JP | disclosed |
| JP-55034206-A | — | — | None | — | — | JP | disclosed |
| EP-3829559-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2026-03-17 | — | — | US | disclosed |
| EP-3200589-B1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-12-23 | — | — | US | disclosed |
| US-4770810-A | Organic compound having a smectic phase A, and a mixture comprising this compound | THOMSON-CSF (FR) | 1988-09-13 | — | — | US | disclosed |
| EP-0222157-A2 | Resin composition | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1987-05-20 | — | — | EP | disclosed |
| US-4545921-A | Liquid crystals having a type A smectic phase | THOMSON-CSF (FR) | 1985-10-08 | — | — | US | disclosed |
| US-4544767-A | HYDROGENATION CATALYST | PHILLIPS PETROLEUM COMPANY (US) | 1985-10-01 | — | — | US | disclosed |
| JP-S57192336-A | TRANS-4-(TRANS-4'-ALKYLCYCLOHEXYL)CYCLOHEXANECARBOXYLIC ACID PHENYL ESTER | CHISSO CORP | 1982-11-26 | — | — | JP | disclosed |
| US-4283420-A | ANTICONVULSANTS, ANTIANAPHYLACTIC AGENTS, ANTIPSYCHOTIC AGENTS | LABAZ (FR) | 1981-08-11 | — | — | US | disclosed |
| US-4279770-A | Liquid crystal 2,3-dicyano-hydroquinone derivatives | CHISSO CORPORATION (JP) | 1981-07-21 | — | — | US | disclosed |
| JP-S5534206-A | NEMATIC LIQUID CRYSTAL FOR DISPLAY UNIT | HITACHI LTD | 1980-03-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | CYP2C19 847/4885MEN1 3312/4885KMT2A 3078/4885 |
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, CHRNA6, NR3C2 | CYP2C19 528/4885MEN1 4861/4885KMT2A 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.